TBG Diagnostics (OTCMKTS:TDLAF) vs. FitLife Brands (NASDAQ:FTLF) Financial Comparison

FitLife Brands (NASDAQ:FTLF) and TBG Diagnostics (OTCMKTS:TDLAF) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership and risk.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for FitLife Brands and TBG Diagnostics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FitLife Brands	0	0	0	0	N/A
TBG Diagnostics	0	0	0	0	N/A

Profitability

This table compares FitLife Brands and TBG Diagnostics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
FitLife Brands	12.48%	28.66%	15.09%
TBG Diagnostics	N/A	N/A	N/A

Institutional & Insider Ownership

2.3% of FitLife Brands shares are held by institutional investors. 61.2% of FitLife Brands shares are held by company insiders. Comparatively, 3.6% of TBG Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares FitLife Brands and TBG Diagnostics’ gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FitLife Brands	$60.68 million	2.53	$5.30 million	$1.48	22.55
TBG Diagnostics	$2.33 million	1.02	$530,000.00	N/A	N/A

FitLife Brands has higher revenue and earnings than TBG Diagnostics.

Volatility and Risk

FitLife Brands has a beta of 1.01, indicating that its stock price is 1% more volatile than the S&P 500. Comparatively, TBG Diagnostics has a beta of -12.38, indicating that its stock price is 1,338% less volatile than the S&P 500.

Summary

FitLife Brands beats TBG Diagnostics on 9 of the 9 factors compared between the two stocks.

About FitLife Brands

FitLife Brands, Inc. provides nutritional supplements for health-conscious consumers in the United States and internationally. The company provides weight loss, sports nutrition, and general health products; sports nutrition products; weight loss and sports nutrition products; sports nutrition and general wellness formulations with an emphasis on natural, vegan, and organic ingredients; and male health and weight loss products, as well as other diet, health, and sports nutrition supplements and related products; and value-oriented sports nutrition and weight loss products. It offers MRC products which includes general health supplements; and natural skincare and beauty products. In addition, it markets its products under the brand names of NDS Nutrition, PMD Sports, SirenLabs, CoreActive, Nutrology, Metis Nutrition, iSatori, BioGenetic Laboratories, Energize, Dr. Tobias, All-Natural Advice, and Maritime Naturals through franchised stores, as well as through retail locations, which include specialty, mass, and online. The company was formerly known as Bond Laboratories, Inc. and changed its name to FitLife Brands, Inc. in September 2013. FitLife Brands, Inc. was incorporated in 2005 and is headquartered in Omaha, Nebraska.

About TBG Diagnostics

TBG Diagnostics Limited, a molecular diagnostics company, develops, manufactures, and markets molecular diagnostics kits, instruments, and services in Taiwan and China. It provides ExProbe HLA and HPA kits for human leukocyte antigen (HLA) and human platelet antigens (HPA) allele genotyping, which uses real time polymerase chain reaction (PCR) techniques with sequence specific primers and probes; Morgan SSP HLA kits for determining HLA alleles using PCR techniques with sequence specific primers; HLAssure SBT HLA Kits for transplantation donor selection; and AccuType SBT analysis software to analyze sequences from all ab1 based files. The company also offers Morgan SSPal HLA Typing Analysis Software, a gel result interpretation software; HLA typing services that offer low to high resolution using PCR fragment analysis (SSP) and DNA sequencing (SBT); QPCR Q6000, a six-channel real time PCR instrument; QzNGS NGS that provides high resolution HLA genotyping; and COVID-19 testing kits. It serves clinical labs, blood centers, and bone marrow registry labs. The company was formerly known as Progen Pharmaceuticals Limited and changed its name to TBG Diagnostics Limited in December 2015. TBG Diagnostics Limited was incorporated in 1989 is based in Greenslopes, Australia.